Sutro Biopharma
STRO
108 hedge funds and large institutions have $194M invested in Sutro Biopharma in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 43 increasing their positions, 32 reducing their positions, and 18 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 32
0.28% more ownership
Funds ownership: 8.95% → 9.23% (+0.28%)
10% less funds holding
Funds holding: 120 → 108 (-12)
23% less capital invested
Capital invested by funds: $252M → $194M (-$57.3M)
25% less call options, than puts
Call options by funds: $3K | Put options by funds: $4K
61% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$12.5M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$2.42M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.44M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.41M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$520K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$3.07M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.43M |
| 3 |
Millennium Management
New York
|
-$1.15M |
| 4 |
Man Group
London,
United Kingdom
|
-$1.08M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$995K |
STRO Hedge Fund Activity: Q3 2023 in Review
108 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q3 2023, worth a combined $194M — down 23% from $252M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of STRO and 7 opened new positions — a net loss of 11 holders — while 32 trimmed existing stakes and 43 added.
The largest buyer was Adage Capital Partners, adding an estimated $12.5M. The largest seller was Rubric Capital Management (New York), cutting an estimated $3.07M.
- 108 institutional investors held Sutro Biopharma (STRO) as of Q3 2023, down from 120 in Q2 2023.
- Funds reported $194M of Sutro Biopharma stock for Q3 2023, down 23% quarter-over-quarter.
- 7 funds opened new Sutro Biopharma positions in Q3 2023 and 18 closed out, a net change of -11 holders.
- The largest Sutro Biopharma buyer in Q3 2023 was Adage Capital Partners, an estimated $12.5M added.
- The largest Sutro Biopharma seller in Q3 2023 was Rubric Capital Management (New York), an estimated $3.07M sold.
Based on aggregated 13F filings for Q3 2023.